Inhibikase Therapeutics, Inc. (IKT) — Total Liabilities
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $8.30M | +122.3% |
| 2024 | $3.73M | +5.8% |
| 2023 | $3.53M | -9.5% |
| 2022 | $3.90M | -3.8% |
| 2021 | $4.05M | -18.9% |
| 2020 | $5.00M | — |
| Fiscal Year | Total Liabilities | Change YoY |
|---|---|---|
| 2025 | $8.30M | +122.3% |
| 2024 | $3.73M | +5.8% |
| 2023 | $3.53M | -9.5% |
| 2022 | $3.90M | -3.8% |
| 2021 | $4.05M | -18.9% |
| 2020 | $5.00M | — |